Chemomab Therapeutics Ltd (CMMB)
$0.7
+0.11
(+18.64%)▲
Insights on Chemomab Therapeutics Ltd
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 111.2%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 342.9%
Performance
- $0.62$0.70$0.70
11.43%
Downside
Day's Volatility :11.43%
Upside
0.0%
- $0.42$1.89$0.70
40.0%
Downside
52 Weeks Volatility :77.78%
Upside
62.96%
Returns
| Period | Chemomab Therapeutics Ltd | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 10.07% | -0.7% | 0.0% |
6 Months | -28.05% | 6.6% | 0.0% |
1 Year | -64.46% | 3.7% | -1.5% |
3 Years | -98.29% | 14.0% | -21.8% |
Highlights
Market Capitalization | 9.4M |
Book Value | $1.2 |
Earnings Per Share (EPS) | -2.06 |
Wall Street Target Price | 7.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -48.8% |
Return On Equity TTM | -91.02% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -25.4M |
Diluted Eps TTM | -2.06 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 900.0%
Technicals Summary
Sell
Neutral
Buy
Chemomab Therapeutics Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Chemomab Therapeutics Ltd | -25.83% | -28.05% | -64.46% | -98.29% | -99.96% |
 Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
 Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
 Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
 Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Chemomab Therapeutics Ltd | NA | NA | NA | 0.0 | -0.91 | -0.49 | NA | 1.2 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Chemomab Therapeutics Ltd | Buy | $9.4M | -99.96% | NA | 0.0% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Institutional Holdings
Advisory Services Network, LLC
0.04%
Corporate Announcements
Chemomab Therapeutics Ltd Earnings
Chemomab Therapeutics Ltd’s price-to-earnings ratio stands at None
Read More
Company Information
chemomab ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. chemomab is making great strides with its novel cm-101 proprietary platform, which hinders the fundamental function of the soluble chemokine ccl24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders. cm-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets ccl24. chemomab has shown that cm-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action. chemomab is actively advancing cm-101 into phase 2 studies to treat patients with liver fibrosis (primary sclerosing cholangitis and non-alcoholic steatohepatitis) and patients suffering from skin and lung fibrosis (systemic sclerosis).
Organization | Chemomab Therapeutics Ltd |
Employees | 0 |
CEO | Dr. Adi Mor George Ph.D. |
Industry | Healthcare |
